Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Short term Debt (2022 - 2025)

Historic Short term Debt for Cue Biopharma (CUE) over the last 4 years, with Q3 2025 value amounting to $1.5 million.

  • Cue Biopharma's Short term Debt fell 6355.0% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 6355.0%. This contributed to the annual value of $4.3 million for FY2024, which is 933.64% up from last year.
  • As of Q3 2025, Cue Biopharma's Short term Debt stood at $1.5 million, which was down 6355.0% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, Cue Biopharma's Short term Debt peaked at $4.3 million during Q4 2024, and registered a low of $1.0 million during Q3 2022.
  • In the last 4 years, Cue Biopharma's Short term Debt had a median value of $4.0 million in 2023 and averaged $3.2 million.
  • Its Short term Debt has fluctuated over the past 5 years, first surged by 30000.0% in 2023, then crashed by 6355.0% in 2025.
  • Over the past 4 years, Cue Biopharma's Short term Debt (Quarter) stood at $2.0 million in 2022, then soared by 101.88% to $4.0 million in 2023, then grew by 9.34% to $4.3 million in 2024, then plummeted by 66.35% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $2.4 million for Q2 2025, and $3.4 million during Q1 2025.